Québec City, January 29, 2015 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that, while pursuing negotiations with potential distribution partners, the Company is strengthening its management team with the addition of two new executives. Mr. James (Jim) Wetzel and Mrs Paule De Blois have joined TSO3, respectively as Vice President of Sales and Marketing and General Manager, Administration. The Company will benefit from the significant experience of these new executives.
“This is an exciting time for TSO3. With the US clearance for the new STERIZONE® VP4 Sterilizer in hand, we must initiate selected activities targeting increased awareness of our technology in the US market. We must also prepare to train and support third party sales and service personnel”, stated Mr. R.M. (Ric) Rumble, President and CEO of TSO3. “Experienced leadership is essential to effectively execute our strategy, and I am very pleased to welcome Jim and Paule to the team.
About the STERIZONE® VP4 low temperature sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3’s unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
More information about the STERIZONE® VP4 Sterilizer is available through TSO3’s website, under the Products section: https://www.tso3.com/en/products/sterizone-vp4/
Founded in 1998, TSO3’s activities encompass research, development, commercialization and licensing of sterilization processes for heat-sensitive medical devices, related equipment, accessories and consumable supplies. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company’s Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts